Reports by Industry
Reports by Company
- Company Analysis(173)
- Company Profile(60)
Global EPO Biosimilars Market Outlook 2018
Format : 
Adobe Reader (PDF) Upto 24 hour delivery
Publish Date : Feb, 2014| No. of Pages : 45
Please make your selection :
Electronic Access - Single User License
US$ 400.00
CD-ROM Mail Delivery
US$ 500.00
Hard Copy Mail Delivery
US$ 500.00
Electronic Access - Multi-User License
US$ 800.00
1. Analyst View
2. Research Methodology
3. Biologics Market Outlook to 2018
3.1 Market Size
3.2 Market Segmentation
4. Market Trends & Drivers
4.1 Emerging Markets to Play a Pivotal Role in the Growth of Biosimilars
4.2 Rising Business Alliances Aiding in Biosimilar Development
4.3 Governments Realizing the Potential in Biosimilars, Encouraging Industry Growth
5. Biosimilars Market Outlook to 2018
6. Erythropoietin Market Outlook to 2018
6.1 Scientific Insight
6.2 Market Analysis
6.3 EPO Biosimilars Products - Marketed and Under-Pipeline
7. Competitive Landscape
7.1 Hospira
7.2 Sandoz GmbH
7.3 Stada
7.4 Hexal AG
7.5 Medice Arzneimittel Pütter GmbH & Co.
7.6 Teva
7.7 LG Life Sciences
7.8 Dr. Reddy's Labs (DRL)
7.9 Biocon
7.10 Intas Pharmaceuticals
7.11 Reliance Life Sciences
7.12 3 SBio Inc
Not able to find data you are looking for? Ask our Research Analyst.
media citation
- testtest
19 Jan, 2024 - Yourstory.com News @ Foodtech startup Swiggy launches Health Hub in Chennai
23 Mar, 2021 - Yourstory.com News @ Zomato forays into dietary supplements, makes its own 'made in India' brand
16 Mar, 2021 - View more
get in touch
Copyright © 2018, RNCOS, 2002-2018
About Us
Terms & Policy
Contact